Free Trial
NASDAQ:RENB

Renovaro (RENB) Stock Price, News & Analysis

Renovaro logo
$0.39 -0.08 (-16.49%)
Closing price 04:00 PM Eastern
Extended Trading
$0.41 +0.02 (+5.45%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Renovaro Stock (NASDAQ:RENB)

Key Stats

Today's Range
$0.37
$0.51
50-Day Range
$0.47
$1.19
52-Week Range
$0.37
$2.97
Volume
1.55 million shs
Average Volume
899,511 shs
Market Capitalization
$62.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Remove Ads

Renovaro Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
14th Percentile Overall Score

RENB MarketRank™: 

Renovaro scored higher than 14% of companies evaluated by MarketBeat, and ranked 874th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Renovaro.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Renovaro is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Renovaro is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Renovaro has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Renovaro's valuation and earnings.
  • Percentage of Shares Shorted

    6.78% of the float of Renovaro has been sold short.
  • Short Interest Ratio / Days to Cover

    Renovaro has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Renovaro has recently decreased by 4.63%, indicating that investor sentiment is improving.
  • Dividend Yield

    Renovaro does not currently pay a dividend.

  • Dividend Growth

    Renovaro does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.78% of the float of Renovaro has been sold short.
  • Short Interest Ratio / Days to Cover

    Renovaro has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Renovaro has recently decreased by 4.63%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Renovaro this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for RENB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Renovaro to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Renovaro insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.72% of the stock of Renovaro is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    71.41% of the stock of Renovaro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Renovaro's insider trading history.
Receive RENB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renovaro and its competitors with MarketBeat's FREE daily newsletter.

RENB Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Renovaro Biosciences Buys AI-Driven BioSymetrics
See More Headlines

RENB Stock Analysis - Frequently Asked Questions

Renovaro's stock was trading at $0.8355 on January 1st, 2025. Since then, RENB stock has decreased by 53.0% and is now trading at $0.3926.
View the best growth stocks for 2025 here
.

Renovaro Inc. (NASDAQ:RENB) released its quarterly earnings results on Wednesday, February, 19th. The company reported ($0.02) earnings per share for the quarter.

Shares of RENB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Renovaro investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

Last Earnings
2/19/2025
Today
4/04/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RENB
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-80,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.52 per share
Price / Book
0.73

Miscellaneous

Free Float
124,244,000
Market Cap
$60.47 million
Optionable
Optionable
Beta
0.42
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:RENB) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners